You have no items in your shopping cart.
Hetero became first Indian company to receive DGCI’s approval for hepatitis C drug
Indiainfoline Hetero became first Indian company to receive DGCI’s approval for hepatitis C drugJagran JoshHyderabad-based Hetero Drugs on December 2015 announced that it received the approval of Drug Controller General of India (DCGI) to launch fixed-dose combination therapy Ledipasvir-Sofosbuvir. The product will be available under the brand name …Hepatitis C drug: Hetero gets DCGI nod. The HinduHetero receives DCG(I) approval for fixed-dose combination therapy ‘Ledipasvir .
It is a growing public health concern, particularly in developing countries. In India alone, it is estimated that 12-18 million patients are infected with Hepatitis C which is several fold greater than those with HIV/AIDS. Untreated chronic hepatitis C increases the risk of cirrhosis of liver, liver failure and hepatocellular carcinoma.